Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 7:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 641 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Lacrimal Apparatus Disease Clear all
Completed Phase 3 Interventional Results available

Perfluorohexylcotane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Gobi Study)

NCT04139798
View directory record Official record
Conditions
Dry Eye Disease (DED)
Interventions
NOV03, Placebo
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
599 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
29
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Glendale, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Sep 30, 2026, 7:48 PM EDT
Completed Phase 2 Interventional

The Study Evaluating the Efficacy and Safety of OK-101 in Subjects With Dry Eye Disease

NCT05759208
View directory record Official record
Conditions
Dry Eye Disease
Interventions
OK-101, Placebo
Drug
Lead sponsor
Okyo Pharma Ltd
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
6
States / cities
Newport Beach, California • Colorado Springs, Colorado • Louisville, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2024 · Synced Sep 30, 2026, 7:48 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Ocular Surface Dry Eye Microbiome

NCT02306668
View directory record Official record
Conditions
Dry Eyes
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 3, 2014 · Synced Sep 30, 2026, 7:48 PM EDT
Completed Phase 2Phase 3 Interventional Results available

CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)

NCT03292809
View directory record Official record
Conditions
Dry Eye Disease
Interventions
CyclASol topical ocular, eye drops, Vehicle topical ocular, eye drops
Drug
Lead sponsor
Novaliq GmbH
Industry
Eligibility
18 Years and older
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
9
States / cities
Newport Beach, California • Torrance, California • Indianapolis, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2022 · Synced Sep 30, 2026, 7:48 PM EDT
Recruiting Phase 2 Interventional

An Exploratory Efficacy and Safety Study of DFL24498 Topical Ophthalmic Solution Compared With Vehicle in Participants With Dry Eye Disease

NCT07503886
View directory record Official record
Conditions
Dry Eye Disease (DED)
Interventions
DFL24498, Vehicle
Drug · Other
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years and older
Enrollment
417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
24
States / cities
Chandler, Arizona • Azusa, California • Glendale, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Sep 30, 2026, 7:48 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of Maintaining Visual Performance in Participants Who Engage in Electronic Visual Tasking While Using Restasis®

NCT02554981
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Cyclosporine 0.05% Ophthalmic Emulsion
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 55 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Andover, Massachusetts • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Sep 30, 2026, 7:48 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Efficacy of FreshKote and Systane for the Treatment of Dry Eye and Improvement of Osmolarity

NCT01386073
View directory record Official record
Conditions
Dry Eye
Interventions
FreshKote, Systane
Drug
Lead sponsor
Innovative Medical
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
Lake Villa, Illinois • Chesterfield, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 14, 2012 · Synced Sep 30, 2026, 7:48 PM EDT
Withdrawn Not applicable Interventional

Efficacy of Pulsed Light Therapy for Meibomian Gland Dysfunction and Dry Eye Syndrome

NCT01917539
View directory record Official record
Conditions
Meibomian Gland Dysfunction, Dry Eye Syndrome
Interventions
Sham Treatment, Pulsed Light Therapy
Device
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 28, 2018 · Synced Sep 30, 2026, 7:48 PM EDT
Completed Phase 2 Interventional

Determination of the Optimum Delivery Route for Botulinum Toxin A in Patients With Epiphora

NCT01282541
View directory record Official record
Conditions
Epiphora
Interventions
Botulinum Toxin Type A
Drug
Lead sponsor
Merbs, Shannath, M.D., Ph.D.
Individual
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 12, 2012 · Synced Sep 30, 2026, 7:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Tobramycin Tear Concentrations

NCT00695435
View directory record Official record
Conditions
Dry Eye
Interventions
TOBRADEX Ophthalmic Suspension, Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension, TOBREX Ophthalmic Solution
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2010 · Synced Sep 30, 2026, 7:48 PM EDT
Withdrawn Phase 4 Interventional

Hyaluronic Acid Gels for Lower Lid Retraction

NCT01838252
View directory record Official record
Conditions
Ectropion
Interventions
Hyaluronic acid, Saline
Procedure
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2014 · Synced Sep 30, 2026, 7:48 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren's Syndrome

NCT04496960
View directory record Official record
Conditions
Sjogren's Syndrome
Interventions
tofacitinib, Placebo
Drug · Other
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
18 Years to 75 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Sep 30, 2026, 7:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Multi-Colored Placido Disk Viability

NCT02148497
View directory record Official record
Conditions
Dry Eye, Sjogren's Disease, Healthy
Interventions
Multi-colored Placido disk imaging
Procedure
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 89 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 5, 2018 · Synced Sep 30, 2026, 7:48 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Carboxymethylcellulose Artificial Tears on the Eye Microbiome

NCT05292755
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Carboxymethylcellulose (CMC) Artificial Tears, Preservative-free, CMC-free Artificial Tears (control)
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 20, 2023 · Synced Sep 30, 2026, 7:48 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study to Evaluate the Efficacy of Lifitegrast in Subjects With Dry Eye

NCT01743729
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Lifitegrast, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
31
States / cities
Artesia, California • Hemet, California • Lancaster, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Sep 30, 2026, 7:48 PM EDT
Completed No phase listed Observational

An Observational Study to Assess Optive MEGA-3 (OM3) on Dry Eye Symptoms and Quality of Life of Adult Participants With Mild to Moderate Dry Eye Disease (DED)

NCT06439394
View directory record Official record
Conditions
Dry Eye
Interventions
Optive MEGA-3 (OM3)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Sep 30, 2026, 7:48 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy Assessment of Vismed® (Sodium Hyaluronate) for the Treatment of Dry Eye Syndrome

NCT00599716
View directory record Official record
Conditions
Dry Eye Disease
Interventions
sodium hyaluronate, vehicle
Drug
Lead sponsor
Lantibio
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
10
States / cities
Boynton Beach, Florida • Miami, Florida • Stuart, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2009 · Synced Sep 30, 2026, 7:48 PM EDT
Completed Not applicable Interventional Results available

The Effect of Systane Ultra Lubricant Eye Drops (FID 112903) on Visual Performance

NCT00673764
View directory record Official record
Conditions
Dry Eye
Interventions
Systane Ultra Lubricant Eye Drops, Optive Lubricant Eye Drops
Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Months and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
North Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Sep 30, 2026, 7:48 PM EDT
Completed Phase 3 Interventional

A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye

NCT02634853
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
1% Tavilermide Ophthalmic Solution, Placebo Ophthalmic Solution
Drug
Lead sponsor
Mimetogen Pharmaceuticals USA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
429 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Louisville, Kentucky • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 16, 2019 · Synced Sep 30, 2026, 7:48 PM EDT
Suspended No phase listed Observational

Sjogren's Lung Study

NCT04843345
View directory record Official record
Conditions
Sjogren's Syndrome, Interstitial Lung Disease, Primary Pulmonary Lymphoma (Disorder), Chronic Bronchiolitis, Bronchiectasis, Lung Diseases, Cystic Lung Disease, Lymphocytic Interst. Pneumonitis
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Sep 30, 2026, 7:48 PM EDT
Completed Phase 4 Interventional Results available

Efficacy of Zylet vs. Lotemax for the Treatment of Ocular Surface Inflammation/MGD/Blepharitis

NCT01456780
View directory record Official record
Conditions
Meibomian Gland Dysfunction, Posterior Blepharitis
Interventions
Loteprednol/tobramycin, Loteprednol, B+L Advanced Eye Relief Lubricant Drop
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Sep 30, 2026, 7:48 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Dextenza With ILUX for Treatment of MGD

NCT04658927
View directory record Official record
Conditions
Meibomian Gland Dysfunction, Evaporative Dry Eye
Interventions
Dexamethasone, 0.4mg, Prednisone acetate, Control
Drug · Other
Lead sponsor
Warrenville Eyecare
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Warrenville, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 27, 2022 · Synced Sep 30, 2026, 7:48 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of DE-110 Ophthalmic Suspension for the Treatment of Dry Eye Disease

NCT01239069
View directory record Official record
Conditions
Dry Eye
Interventions
DE-110 ophthalmic suspension high dose, DE-110 ophthalmic suspension low dose, Placebo
Drug · Other
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
14
States / cities
Inglewood, California • Newport Beach, California • Petaluma, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 21, 2014 · Synced Sep 30, 2026, 7:48 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

The DEPOT Study (Dry Eye Prescription Options for Therapy)

NCT04911361
View directory record Official record
Conditions
Dry Eye
Interventions
Dexamethasone
Drug
Lead sponsor
Research Insight LLC
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
3
States / cities
Hemet, California • Laguna Hills, California • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 3, 2022 · Synced Sep 30, 2026, 7:48 PM EDT